BioCentury | Feb 1, 2020
Tools & Techniques

Cellular fluorescence assay to assess allosteric modulator potency in drug discovery

Karolinska, Pasteur and UCSD researchers have developed a cellular fluorescence assay that can efficiently screen for potent transcription factor allosteric modulators during lead identification. Unlike compounds that work by binding targets’ active sites, allosteric modulators...
BC Extra | Jun 8, 2019
Politics & Policy

NIDA Director Volkow calls on biotechs to step up to the plate in opioid crisis

Director of NIH’s National Institute On Drug Abuse Nora Volkow called on investors and biotech companies to roll up their sleeves and help end the opioid crisis by contributing their intellectual and financial resources to...
BC Week In Review | Sep 7, 2018
Clinical News

Bifunctional agonist could treat pain, opioid dependency

A team from Astraea Therapeutics LLC (Mountain View, Calif.) and Wake Forest Baptist Medical Center developed a bifunctional agonist targeting two opioid receptors that could treat pain without opioid-related side effects and reverse opioid dependency....
BC Extra | Aug 29, 2018
Preclinical News

Bifunctional agonist could treat pain, opioid dependency

A team from Astraea Therapeutics LLC (Mountain View, Calif.) and Wake Forest Baptist Medical Center developed a bifunctional agonist targeting two opioid receptors that could treat pain without opioid-related side effects and reverse opioid dependency....
BC Extra | Jun 1, 2017
Politics & Policy

NIH seeks public-private partnerships to fight opioid crisis

In an article published in the New England Journal of Medicine and a blog post , NIH Director Francis Collins and National Institute on Drug Abuse (NIDA) Director Nora Volkow outlined a plan to speed research...
BC Innovations | Sep 15, 2016
Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc. 's anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical...
BC Innovations | Sep 1, 2016
Targets & Mechanisms

Biased against pain

In a departure from the rote tweaking of morphinan structures to find better and safer opioids, an academic collaboration has used a powerful, computer-based screen of more than 3 million molecules to identify a new...
BioCentury | Aug 19, 2013
Strategy

Delivering on NMEs

With the unveiling of three new preclinical programs, Alkermes plc is fulfilling ambitions first stated in 2011 to evolve from partnering drug delivery technology to discovering and developing its own in-house products, including its first...
BioCentury | Mar 18, 2013
Emerging Company Profile

gIcare: Colonoscopy comfort

gIcare pharma Inc. is developing a pipeline of non-sedating colonic analgesic compounds to provide new and lower cost alternatives for pain management during colonoscopy. Sedation during endoscopy has become routine practice among gastroenterologists, even though...
BC Innovations | Jan 20, 2011
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain m-Opioid receptor (OPRM1; MOR); opioid receptor-d1 (OPRD1; DOR) Studies in mice identified tetrapeptide bifunctional agonists of OPRM1 and OPRD1 that...
Items per page:
1 - 10 of 230